Organization
Jennifer Woyach
3 clinical trials
Clinical trial
Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-InStatus: Completed, Estimated PCD: 2022-09-20
Clinical trial
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31